Company Overview and News
2018-09-03 seekingalpha - 6
This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn’s 13F portfolio on a quarterly basis. It is based on Icahn’s regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Carl Icahn’s Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q1 2018.
VLTCP CQP CVI SDRPQ FCX TPCA VMW ENZN AFNL HRI NWL EGN VLTCW CI WBT VKSC ARII LNG GLPI SD XRX IEP NAV CNDT SDOCQ HLF UAN DVMT ERI CVRR VLTC MTW SDRXP HTZ SDRXQ
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,B]3(#,X/CYS=')E86T-"FC>[email protected][email protected]
Document Table of Contents
American Railcar Industries (ARII - Free Report) just came out with quarterly earnings of $0.61 per share, missing the Zacks Consensus Estimate of $0.63 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items.
CHICAGO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- GATX Corporation (NYSE:GATX) today announced that it has entered into an agreement with American Railcar Industries, Inc. (“ARI”) to purchase 7,650 newly built railcars. The order encompasses a mix of tank and freight cars that deliver over a five-year period, beginning in April 2019. The agreement also includes an option to order up to an additional 4,400 railcars, subject to certain restrictions.
GATX ARII GMTA GMT
ST. CHARLES, Mo., July 24, 2018 (GLOBE NEWSWIRE) -- American Railcar Industries, Inc. (NASDAQ:ARII) (“ARI” or the “Company”) announced today that it will discuss its second quarter 2018 results on a conference call on August 1, 2018 at 10:00 am (Eastern Time). These results will be made available on the Investor Relations page at americanrailcar.com.
Editor's note: Seeking Alpha is proud to welcome Benen Ling as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
GE GEC ARII WFT BHGE GNE AOMFF UTX ALSMY ALO
In December 2017 Trinity Industries Inc.’s (NYSE:TRN) announced that they would spin-off their infrastructure related businesses into its own separate entity called Arcosa Inc. (Arcosa). Arcosa is expected to have approximate revenue of $1.5 billion post spin, leaving TRN with the rail-related businesses (Rail and Railcar Leasing) and approximate forecasted revenue of $2.4 billion (May 2018 Investor Presentation).
GFN GFNCP ARII GFDV TRN GFNSL
Small-cap companies have historically outperformed the S&P 500: both because of the higher risk involved and because of market inefficiencies.
2018-05-21 seekingalpha - 7
This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn's 13F portfolio on a quarterly basis. It is based on Icahn's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking Carl Icahn's Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017.
VLTCP CQP CVI SDRPQ FCX PYPL TPCA AFSS AFST ENZN HRI NWL VLTCW WBT VKSC 8685 EBAY ARII AVF LNG GLPI KDUS AIG XRX IEP SD NAV CNDT SDOCQ HLF UAN ERI CVRR AFSI VLTC MTW SDRXP HTZ SDRXQ
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET